In Vivo Preclinical Oncology PDX Models and Studies

Assess the potential pharmacological profile of your drug candidates by employing a set of validated in vivo models. LIDE offers a comprehensive range of solutions to measure the effectiveness and pharmacological characteristics of your drug candidates to maximize success in the clinical stage. 

Each study is available as a stand-alone service or as part of an end-to-end preclinical, IND-enabling program. Each engagement begins with a complementary consultative call with our science team, so that we can match your study and budget needs with an exact study plan.

MiniPDX Mouse

MiniPDX®: An In-Vivo 3D Organoid That Gets Results in 7 Days

Our proprietary MiniPDX® and IO-FIVE tests provide fast and cost effective feedback to bridge from in-vitro to in-vivo studies.

  • Results in 7-14 days
  • Supports wider range of drugs and dosing protocols than in-vitro methods
  • More cost effective than traditional PDX
  • 82% correlated with clinical results
Learn More

PDX Mouse Database Icon

2000 Patient Derived Xenograft (PDX) Models

LIDE’s industry leading PDX library offers our clients access to unique, patient-consented, highly characterized, low-passage tumors.

  • 50 oncology indications covered
  • World's largest biobank of pretreated models
  • 900 models with full treatment history
  • Variant rich: naturally-derived resistance and rare mutations
Learn More

CDX Icon

Cell Line Derived Xenograft (CDX) Models

CDX models are a well established and a widely used in vivo option for preclinical drug efficacy testing. LIDE has a growing bank ready for client application.

  • 50 models ready to use
  • New models established at minimal client cost
  • Cost effective and fast turnaround time
Learn More

Orthotopic Models

Orthotopic Models

Leverage cell-line based orthotopic models, implanted at the organ of origin, closely mirroring the natural tumor environment and providing better clinical predictivity than subcutaneous approaches.

  • Faithfully replicate the natural tumor microenvironment
  • High translational value
  • Validation with IVIS imaging
Learn More

Syngeneic Mouse  Model

Syngeneic Models

Syngeneic mouse models offer an ideal platform for conducting early proofs of concept of (IO) therapeutics.

  • Murine syngeneic or chimeric humanized models available
  • Evaluate MOAs, kinetics, toxicity and potency
  • Cost efficient vs. more complex humanized models
Learn More

Humanized Mouse Model

Humanized Models

HuPBMC reconstituted and co-inoculated models provide the most human relevant in vivo platform for your human-specific immunotherapy studies.

  • Faster and more cost-effective than full immune cell reconstitution
  • Overcome GvHD issues
  • Several targets available
Learn More